Antibodies. Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). Well documented HT29 and SW480 colon cancer cell lines have been bought from Sigma. Authentication by Sigma. Before use cell lines were tested in house for mycoplasma and were both negative. HT29 and SW480 colon cancer cell lines have not been listed by ICLAC as contaminated cell lines.
Antibodies. The list of DS Know-How to be disclosed by DS to Zymeworks as of the Effective Date is specified in the Exhibit 1.23.
Antibodies. If [***] during the Research Term either Party has a reasonable belief that an Antibody that is being researched or Developed by or on behalf of Prothena (or its Affiliates) Targets a given Collaboration Target, and wishes to confirm whether or not such Antibody Targets such Collaboration Target, then either Party may issue a notice to the other Party with respect thereto (a “Confirmation Notice”). The Parties shall discuss in good faith for a period of [***] ([***]) days whether or not such Antibody Targets the applicable Collaboration Target. In the event that the Parties do not agree in writing within such [***] ([***]) day period whether or not such Antibody Targets the applicable Collaboration Target, either Party may issue a written notice to the other Party requesting the independent evaluation described in Section 2.4.3. [***]
Antibodies. 2.1.4.1.1 Primary antibodies Table 6 Primary antibodies Antibody Supplier Monoclonal/ Polyclonal Species Working dilution
Antibodies. To localize mGluR7, Protein A chromatography purified rabbit polyclonal antibody raised against peptide (C-NSPAAKKKYVSYNN) corresponding to amino acids 899-912 of human mGluR7 was used at concentration 1:500 (Upstate/Millipore, Catalog # 07-239). Immunoblotting studies by the manufacturer on rat brain microsomal preparation probed with anti-mGluR7 (0.5 micrograms/ml) showed a band at 97kD. The rabbit polyclonal anti-mGluR4a antibody (Zymed/Invitrogen, 1:200, Catalog #513100, Lot #60103066A2) was raised against a synthetic peptide derived from the C-terminal 200 amino acids of the rat mGluR4 protein specific for the mGluR4a splice variant. Studies by the manufacturer confirmed the reactivity on Western blots (Mr=93,000- 110,000) using rat brain cell lysate. Tissue from mGluR4 knock out mice is completely devoid of immunostaining when probed with this antibody (Xxxxx, Xxxx et al., unpublished data). Two antibodies, rabbit anti-VGluT1 and guinea pig anti-VGluT2, were used as specific markers of terminals from either the VGluT1-positive corticostriatal or VGluT2- positive thalamostriatal glutamatergic projections. To localize VGlut1, we used commercially available Rabbit anti-VGluT1 (MaB Xxxxxxxxxxxx, Xxx # XXX0-0, Xxx # XX000X, 1:5000). To generate this VGluT1 antibody a peptide from the COOH terminus of the rat vesicular glutamate transporter 1 (rvGluT1), corresponding to amino acids 543– 560 (cATHSTVQPPRPPPPVRDY) was synthesized. A cysteine was added to the peptide to aid its conjugation to the protein carrier keyhole limpet hemocyanin (KLH; Xxxxxx, Rockford, IL). Antisera were obtained from rabbits (Covance) immunized with the conjugated peptide, and the IgG fraction was recovered (Raju, xx.xx. 2006). Previous studies from our laboratory and others using immunoblotting of brain lysate revealed single bands at ~60 kDa. Preadsorbtion of primary antibody with synthetic peptide (0.2–
Antibodies. The Parties acknowledge that the use of any [***] Antibodies in an LCA Product or Unilateral Product shall be subject to the terms and conditions of the [***] Agreement, including without limitation the financial terms as outlined in Exhibit 6. The Parties shall share the payments pursuant to the [***] Agreement [***] in case of an LCA Product. [***] shall be solely responsible for the payments pursuant to the [***] Agreement with respect to a [***] Unilateral Product, and [***] shall be solely responsible for the payments pursuant to the [***] Agreement with respect to a [***] Unilateral Product, and shall reimburse [***] for all payments due under the [***] Agreement for such [***] Unilateral Product. [***] hereby grants to [***] a sublicence under its rights under the [***] Agreement for the [***] Antibodies it being understood that Sections 12.4, 18.6(c) and 18.6(d) of this Agreement shall apply mutatis mutandis to this sublicense, except that the payment structure with respect to the [***] Agreement shall be as set forth in this Section 13.8.
Antibodies. The Parties acknowledge that the use of any [***] Antibodies in an LCA Product or Unilateral Product shall be subject to the terms and conditions of the [***] Agreement. [***] is an [***] (as that term is defined in the [***] Agreement). [***] hereby grants to [***] a sublicense under its rights under the [***] Agreement for the [***] Antibodies it being understood that Sections 12.4, 18.6(c) and 18.6(d) of this Agreement shall apply mutatis mutandis to this sublicense.
Antibodies. As described above, LICENSEE shall have a license that includes the right to commercialize Partnered Antibodies as Products and shall own any Partnered Antibodies and Partnered Antibody Program Patents. LICENSEE acknowledges that it shall have no right to commercialize, license, or assign any rights to commercialize ATX Antibodies and/or Platform Assisted Antibodies not included in a Partnered Antibody Program, regardless of inventorship. For the sake of clarity, the foregoing sentence shall not limit the exercise by LICENSEE, or its Sublicensee, of its rights to enforce Partnered Antibody Program Patents against Third Parties.
Antibodies. Mouse monoclonal antibodies recognizing RT-1A MHC class I molecules (OX18) and rat transferrin receptor (OX26) were purchased from Serotec (UK) 44. Monoclonal antibody RCMV 35, directed against a 29-kDa RCMV protein, has been described previously 45. For flow cytometry experiments, either FITC-conjugated rabbit anti-mouse IgG (Dako A/S, Denmark) or PE-conjugated goat anti-mouse IgG (Xxxxxxx ImmunoResearch Laboratories, West Grove, PA) were used as secondary antibody. Infection The cells were infected at 80-90% confluency, washed with PBS, placed on EMEM containing 2% FCS for 30 min, and washed again with PBS. The virus was diluted in EMEM with 2 % NCS. For flow cytometry experiments, cells were infected with an m.o.i. of 1; for biochemical experiments, cells were infected with an m.o.i. of 3. To increase the efficiency of infection, cells were centrifuged at 700 g at 20 °C for 45 min and placed at 37 °C for another 10-15 min 46. The infection medium was replaced by culture medium containing 2% NCS. For biochemical experiments, RPMI was used for cell culture and infections. Flow cytometry Cell surface expression of MHC class I molecules, transferrin receptor and EGFP were analyzed by flow cytometry using FACSort equipment and Cell Quest software (Becton Xxxxxxxxx, USA). Cells were stained in PBS containing 1% BSA and 10mM NaN3 47. Metabolic labeling, immunoprecipitations and SDS-PAGE For pulse-chase experiments, cells were starved in medium lacking methionine and cysteine at 37 °C for 1 hr. The cells were labeled with 35S Promix (Amersham), and chased in medium with excess of L-cystine and L-methionine for the times indicated in the figures 47. Where indicated, media were supplemented with the proteasome inhibitor carboxybenzyl-leucyl- leucylleucinal (ZL3H). Cells were lysed in Nonidet-P40 lysis buffer containing leupeptin, AEBSF and ZL3H at 4 °C for 30 min. To remove cell debris, lysates were centrifugated at 10,000g for 10 min. Prior to immunoprecipitation, lysates were precleared twice using normal rabbit and normal mouse sera precoupled to mixed (1:1) Protein A- Sepharose and Protein G-Sepharose beads. Immunoprecipitations were performed on precleared lysates at 4 °C for 2-4 h using specific antisera precoupled to Protein A/G Sepharose beads. Subsequently, the beads were washed with NET buffer [50 mM Tris/HCl, pH 7.4/150 mM NaCl/5 mM EDTA/0.5% (v/v) NP-40] supplemented with 0.1% SDS. The immunoprecipitates were boiled in sample buffer [40 mM Tris/HCl, p...
Antibodies. For purposes of the Antibody Sequence List, each Antibody shall be identified by reference to the Antibody Amino Acid Sequence. Medarex shall indicate on such list the date each such Antibody is added to such list, the date that rights with respect to each such Antibody were exercised by Medarex or granted to Kirin, an Affiliate of either Party, or a Third Party, as the case may be, and the respective territory(ies) in which any rights to such Antibody are held or granted.
